Ovarian Cancer Treatment Improved By Novel Medication

Main Category: Cancer / Oncology
Also Included In: Women's Health / Gynecology
Article Date: 01 Nov 2007 - 6:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A new study appearing in International Journal of Gynecological Cancer states that Bevacizumab, a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels, may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.

Ovarian cancer is the fifth most common cancer in women, accounting for nearly 14,000 deaths annually in the United States. Despite the use of chemotherapy treatment, nearly 70 percent of all ovarian cancer patients will eventually succumb to their disease. Consequently, studies have continued to investigate the activity of novel medications in combination with standard therapy to improve overall and disease-free survival in ovarian cancer patients.

Bevacizumab has been studied clinically and was recently approved as a treatment for metastatic colon cancer and non-small cell lung cancer. Currently, Bevacizumab is also being studied as a treatment to improve patient survival rates for breast and kidney cancers. Since Bevacizumab has a unique mechanism of action and a favorable safety profile, the medication is not associated with unreasonable levels of toxicity. However, previous studies have reported that gastro-intestinal perforations and hypertension may be a consequence of treatment involving Bevacizumab. "The results from our research suggest that the combination of Bevacizumab and standard therapy for the treatment of ovarian cancer may be promising, particularly with regard to safety and efficacy," says Dr. Bram Goldstein, co-author of the study.

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

This study is published in Vol. 17 Issue 4 of International Journal of Gynecological Cancer.

Bram H. Goldstein, Ph.D., is Senior Clinical Fellow at Gynecologic Oncology Associates-Newport Beach, Calif.

International Journal of Gynecological Cancer presents papers from throughout the global community of researchers covering many topics including basic science, epidemiology, diagnostic techniques, surgery, radiotherapy, chemotherapy, pathology and experimental studies. The Journal allows you to call on a roster of international experts for the latest research, advice, and knowledge in order to provide the best treatment for your patients. For more information, please visit http://www.blackwellpublishing.com/ijg.

Source: Sean Wagner
Blackwell Publishing Ltd.